Ajinomoto Co., Inc.
AJINF
Other OTC32.75
USD
- -
- -
ISIN
JP3119600009
Return %
Stock
S&P500
1Y
58.06
26.53
3Y
-15.68
76.60
5Y
42.27
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Shigeo Nakamura
- Full Time Employees
- 34,862
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Address
- 15-1, Kyobashi 1-chome Tokyo Japan 104-8315
- IPO Date
- May 15, 2012
- Website
- ajinomoto.co.jp
- Similar Companies
- Business
- Ajinomoto Co., Inc. is a Japan-based global company primarily engaged in the food and amino acid business, founded in 1909 and headquartered in Chuo-ku, Tokyo. The company offers a comprehensive product portfolio including seasonings and processed foods; frozen foods; amino acids for pharmaceuticals, food, and animal nutrition; biopharmaceutical contract development and manufacturing services (CDMO); specialty chemicals; electronic materials such as interlayer insulating films for semiconductors; and personal care ingredients featuring amino acid-based surfactants and biodegradable alternatives to plastic microbeads. Ajinomoto operates across Japan, Asia, the Americas, and Europe, targeting consumer, foodservice, healthcare, pharmaceutical, and industrial markets. Recent major changes include the strategic acquisition of Forge Biologics for $620 million to expand its global gene therapy CDMO business, integrating cutting-edge bioscience into its healthcare segment. In 2025, Ajinomoto sold its entire equity stake in Ajinomoto Althea, a San Diego-based fill-finish CDMO, to PCI Pharma Services, focusing on optimizing its pharmaceutical services operations. The company entered a strategic partnership with Australian plant-based meat producer v2food to accelerate global growth and expand its plant-based protein offerings. Additionally, Ajinomoto has launched new functional materials and sustainable personal care products, leveraging its amino acid technologies under its "AminoScience" platform, reinforcing its commitment to health, wellness, and sustainability across its diverse businesses. Ajinomoto’s business segments include Seasonings & Foods, covering sauces, nutritional foods, solution ingredients, and frozen foods; Healthcare and Others, including pharmaceutical amino acids, biopharmaceutical CDMO services, functional materials, and medical foods; and specialty chemicals and electronic materials. The company serves retail consumers, foodservice operators, healthcare providers, pharmaceutical firms, and industrial clients globally. With approximately 34,860 employees as of 2025 and annual revenues around 1.53 trillion JPY, Ajinomoto continues to develop innovative and sustainable products by harnessing the power of amino acids to improve quality of life worldwide.
Ajinomoto Q4 Earnings: The Good And The Bad